Karen Eves

Merck & Co., Inc., Rahway, NJ, USA (United States) — United States

Medicine · Health Sciences

12h-index1.4kcitations26works7.72yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV/AIDS drug development and treatment(10), Clostridium difficile and Clostridium perfringens research(10), Microscopic Colitis(8), HIV-related health complications and treatments(6), HIV Research and Treatment(5)

Publications26 total

Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial
The Lancet·2026· 4 cited
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial
The Lancet·2026· 3 cited
P-389. Switching to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily Maintains Viral Suppression Through Week 48 in the Presence of Archived NNRTI Resistance-Associated Mutations or M184I/V in Proviral DNA
Open Forum Infectious Diseases·2026Open Access
Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial
Clinical Infectious Diseases·2025· 3 citedOpen Access
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial
The Lancet HIV·2024· 17 cited
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial
The Lancet HIV·2024· 19 cited
Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine
JAIDS Journal of Acquired Immune Deficiency Syndromes·2021· 24 citedOpen Access
Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial
The Lancet HIV·2021· 43 cited
Efficacy of Bezlotoxumab in Trial Participants Infected With <i>Clostridioides difficile</i> Strain BI Associated With Poor Outcomes
Clinical Infectious Diseases·2020· 9 cited
Islatravir in combination with doravirine maintains HIV-1 viral suppression through 96 weeks
Universidad de Chile·2020· 9 citedOpen Access
Islatravir safety analysis through week 48 from a phase 2 trial in treatment naive adults with HIV-1 infection
Universidad de Chile·2020· 2 citedOpen Access
Influence of Diagnostic Method on Outcomes in Phase 3 Clinical Trials of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: A Post Hoc Analysis of MODIFY I/II
Open Forum Infectious Diseases·2019· 10 citedOpen Access
Bezlotoxumab for Clostridium difficile Infection Complicating Inflammatory Bowel Disease
Gastroenterology·2018· 18 citedOpen Access
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence
Clinical Infectious Diseases·2018· 200 citedOpen Access
Characteristics and Outcomes in Patients with C. Difficile Infection (CDI) and Inflammatory Bowel Disease: Bezlotoxumab Versus Placebo
Gastroenterology·2017· 3 cited
Efficacy of Bezlotoxumab in Patients with Recurrent Clostridium Difficile Infection (CDI): Pooled Analysis of Data from the Modify Trials
Gastroenterology·2017
Bezlotoxumab for Prevention of Recurrent <i>Clostridium difficile</i> Infection
New England Journal of Medicine·2017· 832 citedOpen Access
599 The Monoclonal Antibody, Bezlotoxumab Targeting C. difficile Toxin B Shows Efficacy in Preventing Recurrent C. difficile Infection (CDI) in Patients at High Risk of Recurrence or of CDI-Related Adverse Outcomes
Gastroenterology·2016· 7 cited
Efficacy of Bezlotoxumab in Patients Infected With Strains of Clostridium difficile Associated With Poor Outcomes
Open Forum Infectious Diseases·2016· 3 citedOpen Access
Bezlotoxumab Alone and With Actoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients on Standard of Care Antibiotics: Integrated Results of 2 Phase 3 Studies (MODIFY I and MODIFY II)
Open Forum Infectious Diseases·2015· 18 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Stephanie O. Klopfer(12), Marcus Dörr(9), Anjana Grandhi(7), Todd Correll(7), Dale N. Gerding(6), Ciarán P. Kelly(6), Galia Rahav(6), Dalya Güriş(6), Barbara J. Kuter(6), Jean‐Michel Molina(6), Alison Pedley(5), Christopher Bettacchi(5), Mark H. Wilcox(4), Nicholas A. Kartsonis(4), Misoo C. Ellison(4), Yazdan Yazdanpanah(4), C. Anania(4), Michael Robertson(4), Carey Hwang(4), George J. Hanna(4)